PPD Acquires Acurian, Industry Leader in Patient Recruitment and Retention

Wilmington, N.C., August 27, 2013 – Pharmaceutical Product Development, LLC (PPD) today announced it has acquired Acurian, a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry.

“As the biopharmaceutical industry continues to face increasing challenges with the time and cost of drug development, PPD is committed to bringing innovation to the clinical development process to deliver efficiencies for our customers,” David Simmons, chairman and chief executive officer of PPD, said. “Acurian’s best-in-class approach to patient recruitment will be an excellent complement to PPD’sclinical development expertise. Acurian will enable PPD to provide clients industry-leading services that accelerate patient enrollment and support their strategies for data-driven feasibility, site selection and enrollment delivery.”

Providing analytics-driven services to many large- and mid-sized pharmaceutical companies, Acurian manages the entire patient recruitment cycle, from recruitment to enrollment to retention. These services utilize innovative, proprietary and highly predictive software analytics to customize the most efficient and cost-effective approach to recruiting patients for a customer’s clinical trial.

Acurian will continue to operate under its own name as a separate business unit with its existing management team led by Rick Malcolm, who has served as Acurian’s chief executive officer since 2005.

“We are excited about the opportunity to become part of a leading global contract research organization,” Malcolm said. “Combining Acurian’s 15 years of experience in successfully innovating to meet the challenges of patient enrollment and retention with PPD’s full spectrum of drug development services will enable us to merge the expertise of both organizations and offer clients unique solutions for clinical trial feasibility studies and patient recruitment and retention.”

Based in Horsham, Pa., Acurian provides services globally.

About Acurian
Acurian, a subsidiary of PPD, is a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, prescreening and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites or time.

About PPD
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Contacts

Media:
Ned Glascock, PPD
+1 910 558 8760
ned.glascock@ppdi.com

Scott Connor, Acurian
+1 215 323 9028
scott.connor@acurian.com

Investors:
Luke Heagle, PPD
+1 910 558 7585
luke.heagle@ppdi.com